Oppenheimer Releases a Buy Rating on Avita Medical (RCEL)
In a report released yesterday, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Avita Medical (RCEL), with a price target of $45.00. The company’s shares closed last Monday at $27.18.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 20.4% and a 47.0% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.
Avita Medical has an analyst consensus of Strong Buy, with a price target consensus of $42.67.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.